title: [Treatment with interferon and ribavirin of chronic hepatitis C in HIV-infected patients].
abstract: BACKGROUND
  The rapid progression of chronic hepatitis C (CHC) in HIV-infected patients is now the most important cause of morbidity, mortality and hospital admissions. In order to avoid this evolution, the treatment of CHC is a major challenge in these patients.
  
  
  METHODS
  The aim of this study is to evaluate the safety and efficacy of treatment of CHC in HIV-infected patients with subcutaneous IFN (3 MU 3 times a week) plus Ribavirin (RBV) administered per 200 mg dosage depending on their body weight, for 24 weeks for genotype 2 or 3 and 48 weeks for genotype 1 or 4. All the patients have a CD4 count over 150 cells/microl and HIV viral load < 50,000 copies/ml, with or without antiretroviral treatment. We defined sustained response as RNA-VHC below level of detection 24 weeks after the end of treatment.
  
  
  RESULTS
  We included 28 patients in the study, with median age of 36.6 y.o. 82% of the patients were on antiretroviral treatment, with AZT in 60% of them. Genotype distribution was HCV-1 in 50%, HCV-3 in 35.7%, HCV-4 in 10.7% and HCV-2 in 3%. Liver biopsy was performed in all the patients. Adverse events leading to treatment discontinuation occurred in 5 patients (17.8%). The overall sustained response rate in the intent-to-treat analysis was 25.8% (50% for genotype 3 and 14% for genotype 1).
  
  
  CONCLUSIONS
  This therapy provides cure in a rate significantly lower than that seen in HCV-monoinfected individuals, with a similar safety. The modern formulations of IFN (pegylated) will provide new expectatives in this group of patients.
authors.affiliation: Servicio de Medicina Interna-Infecciosas, Hospital Universitario de La Princesa, Madrid. isantosg@hotmail.com
authors.forename: I
authors.initials: I
authors.lastname: Santos Gil
authors.forename: J
authors.initials: J
authors.lastname: Sanz Sanz
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000821:virology; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015497:HIV-1; D016174:Hepacivirus / Q000187:drug effects / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin
vernacular_title: Tratamiento con interferón y ribavirina de la hepatitis crónica por virus C en pacientes con infección por VIH.